– Our Platform
An innovative, targeted approach to treating cancer
Our treatment specifically targets unique features of cancer cells, including externalized phosphatidylserine and tumor cell lysosomes by utilizing a small lysosomal protein known as Saposin C.
– Our Pipeline
A Pipeline-in-a-Product asset with potential for multiple indications
BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.
– clinical trials
Update
Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Resources
Resources
News
Bexion Pharmaceuticals Announces the Addition of Olivia F. Kirtley to Board of Directors
FOR IMMEDIATE RELEASE Covington, KY February 22, 2021 Bexion Pharmaceuticals, Inc. announced today that it has added Olivia F. Kirtley to its Board of Directors. Ms. Kirtley, a Certified Public Accountant and Chartered Global Management Accountant, is a business consultant on strategic, risk and corporate governance issues. She brings to Bexion extensive experience as ... Read More
Bexion Pharmaceuticals Announces Database Lock in Phase 1 Trial of BXQ-350
FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome's roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patients ... Read More